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Abstract
The blood–brain barrier (BBB) is a functional and structural barrier separating the intravascular and neuropil
compartments of the brain. It characterizes the vascular bed and is essential for normal brain functions. Dysfunction
in the BBB properties have been described in most common neurological disorders, such as stroke, traumatic
injuries, intracerebral hemorrhage, tumors, epilepsy and neurodegenerative disorders. It is now obvious that the BBB
plays an important role in normal brain activity, stressing the need for applicable imaging and assessment methods.
Recent advancements in imaging techniques now make it possible to establish sensitive and quantitative methods
for the assessment of BBB permeability. However, most of the existing techniques require complicated and
demanding dynamic scanning protocols that are impractical and cannot be fulfilled in some cases. We review
existing methods for the evaluation of BBB permeability, focusing on quantitative magnetic resonance-based
approaches and discuss their drawbacks and limitations. In light of those limitations we propose two new
approaches for BBB assessment with less demanding imaging sequences: the “post-pre” and the “linear dynamic”
methods, both allow semi-quantitative permeability assessment and localization of dysfunctional BBB with simple/
partial dynamic imaging protocols and easy-to-apply analysis algorithms. We present preliminary results and show
an example which compares these new methods with the existing standard assessment method. We strongly
believe that the establishment of such “easy to use” and reliable imaging methods is essential before BBB
assessment can become a routine clinical tool. Large clinical trials are awaited to fully understand the significance
of BBB permeability as a biomarker and target for treatment in neurological disorders.
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Review
The blood–brain barrier (BBB) is a tightly-regulated,
structural and functional barrier that controls the extracel-
lular neuronal environment within the brain and spinal
cord by limiting the free passage of ions and large mole-
cules into the CNS. BBB functions are often impaired in
common neurological disorders, including stroke, trau-
matic injuries, intracerebral hemorrhage, tumors, epilepsy
and neurodegenerative disorders. BBB dysfunction is often
associated with increased vascular permeability to plasma
constituents, including large proteins, and results in water
influx and brain edema [1]. Recent animal experiments
demonstrated that serum proteins may serve as direct sig-
naling mechanism within the brain resulting in the activa-
tion of astrocytes and the brain immune system, with a
consequent neuronal hyperexcitability and delayed neuro-
degeneration [2]. These studies have highlighted BBB
dysfunction as a potential biomarker for neurological dis-
orders, with the possibility for predicting complications
and neurological outcome after an insult and for deter-
mining novel treatments. Recent advancements in imaging
methods now make it possible to establish sensitive and
quantitative methods for the assessment of BBB perme-
ability, most of which are MRI based.
Methods based on magnetic resonance imaging (MRI)
scans following intravenous injection of MR-visible con-
trast agents containing gadolinium are currently the gold
standard and most commonly used non-invasive imaging
technique for the assessment of BBB impairment in both
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clinical [3-5] and preclinical studies [6]. One of the main
advantages of MRI is the ability to produce multi-
parametric information, allowing high-resolution anatom-
ical information, and assessment of cerebral blood flow
(CBF) and BBB integrity using the same imaging modality
[7]. BBB assessment and permeability quantification are
carried out by either using semi-quantitative methods,
where statistical differences between scans before and after
tracer injection are calculated [8], or by using more quan-
titative approaches based on a dynamic contrast enhanced
MRI (DCE-MRI) [9,10]. These approaches assess the kin-
etics of a contrast agent over time and space to detect
regions with increased vessel permeability. However, most
of the existing techniques require complicated and
demanding dynamic scanning protocols, including tracer
injection during the scan and long scanning sessions.
These imaging protocols in addition to the complex and
computationally-demanding assessment algorithms, make
these dynamic methods impractical and in some cases
even unfeasible, stressing the need for developing “lighter”
and less demanding semi-quantitative methods. One limi-
tation occurs particularly in cases where patients need to
be scanned immediately following a treatment that cannot
be performed inside the magnet, preventing tracer injec-
tion during the scanning as required in DCE-MRI. We de-
scribe and discuss two new methods with less demanding
MRI protocols and easy-to-apply analysis algorithms, the
post-pre and linear dynamic methods. In the post-pre
method only two scans are statistically compared and
analyzed, one scan before the tracer injection and the
other after the tracer injection. Regions with statistically-
significant positive changes are marked as potentially per-
meable and further processed. The linear dynamic method
is a semi-dynamic approach, where scans are taken at se-
veral time points after the tracer injection and analyzed
according to their linear slope. Both proposed methods
overcome some of the limitations described while supply-
ing semi-quantitative assessment comparable to the exist-
ing more complex method.
Methods
We describe two practical approaches for BBB assessment
using DCE-MRI with simpler imaging sequence require-
ments: (1) The “post-pre comparison” method, in which a
statistical comparison is performed between pre- and
post-contrast agent injections; and (2) The “linear
dynamic method”, where the dynamics of the signal
change in multiple scans after contrast agent injection are
calculated, assuming a linear model. Additional back-
ground information on the dynamic DCE-MRI method
can be found in the Appendix. The protocol for this study
was approved by the Soroka University Medical Center
Ethics Committee; a written informed consent was
obtained from all participants. More details on the
(1) Post-pre comparison
The post-pre approach is based on a comparative
analysis between contrast-enhanced MR scans
before and after the intravenous contrast agent
injection. Scans acquired after the injection show
regions with enhanced contrast agent, which can
be quantified by comparison with the
corresponding pre-injection non-contrast scans.
Here we present an advanced method for
permeability assessment based on statistical
analysis of the imaging.
T1-weighted sequences are taken before and 5
minutes after the injection of Gd-DTPA with
dose normalized according to patient’s body
weight (Gd-DTPA 0.5M, 0.1mmol/kg). The scans
are mapped to a standard brain atlas to avoid
artifacts due to head movements and to allow
accurate pixel based comparison between scans
and even between patients for group studies
analysis. This can also be achieved by co-
registration between the pre- and post-injection
images. Regions outside the brain are excluded
from the images and the brain region is
segmented into three tissue classes: gray matter,
white matter and cerebrospinal fluid (CSF). A
brain tissue segment is defined by the
combination of the gray and white matter
regions.
Pre- and post- contrast images are compared in
several steps. First, significantly different pixels
are identified by performing a slice-wise unpaired
t-test (slice-wise processing was chosen for
images with non-isometric voxel size). To this
goal, a neighborhood comparison is applied
where for each pixel, the 3x3 neighborhood (nine
pixels) in the pre- and post- contrast images are
compared. To avoid over-estimation of the
significance level due to redundant t-tests of each
pixel, the FDR (false discovery rate) statistical
correction is applied [11]. Each pixel in the
image is assigned the significance level
accordingly, resulting in a statistical significance
image (P-values). Pixels with P-values < 0.05 are
indicated as statistically significant, resulting in a
binary significance image, where all significant
pixels are assigned with 1 and the non-significant
pixels with 0. The second step involved a
calculation of the enhancement differences
between the pre and post contrast images, which
is computed for each pixel and referred to as E
(percentage value of the intensity difference).
The enhancement-distribution histograms of three
representing regions: eyeball, muscle and a blood
vessel are calculated in order to determine BBB
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breakdown enhancement range for each individual
subject (Figure 1). Muscle is used as a normalization
reference to determine intensity for a “permeable
tissue” with no BBB, and the blood vessel region
used to exclude pixels which represent vessels.
Thus, a pixel is considered as a “permeable brain
region” when its intensity significantly changed after
contrast injection and it was in the range between
the intact BBB (“eyeball”) and the blood vessel. In
order to define an enhancement range, a Gaussian
fit is applied to the histogram that makes it possible
to estimate the mean μ and standard deviation δ of
the enhancement distribution. Significantly different
pixels (taken from the binary significant image)
within the enhancement range of μ ±3δ are
considered to represent brain tissue with leaky BBB
(denoted as potential for leaky BBB, PBBB).
The third step applies a clustering procedure on
the potentially permeable pixels. Neighboring
pixels are aggregated into anatomically-connected
regions (Figure 2E) in order to establish a more
robust assessment of the clinically-relevant brain
regions with a pathological BBB. This was
achieved mathematically by applying image
processing operations which rendered closely-
located pixels into clusters, followed by
component labeling to select pixel clusters with
cluster areas larger than a minimal area. For this
purpose, all the objects inside the image were
ranked according to their area and connectivity
(4-connected). Clusters with areas smaller than
the minimal one are removed from the image. As
a result, regions with a high density of permeable
pixels are highlighted, while single pixels are
removed as potential noise artifacts.
(2) The “linear dynamic method”
In this approach a dynamic study is performed.
There are situations that require the contrast agent
to be injected before the patient enters the scanner.
The time-gap between injection and the beginning
of the scan can be up to several minutes (e.g.,
following a trans-cranial magnetic stimulation).
Under such conditions, the standard two-
compartment model cannot be used, since the
arterial input function (AIF) cannot be estimated.
Quantitative analysis can be carried out by fitting a
linear curve to the dynamic scan intensities. To
allow inter-scan comparisons, the time between the
injection and the scan should be similar. That is, a
signal s (t) is fitted to a linear curve: s(t) = A · t + B.
The slope (A) can be interpreted as the rate of
wash-in or wash-out of the contrast agent, whereas
the intercept (B) represents the relative amount of
contrast agent at the beginning of scanning. A
“goodness of fit” map (R2) can also be created. Areas
with different anatomical properties are
hypothesized to demonstrate different parameters
(i.e. blood vessels should display a relatively high
intercept and a negative slope with a large absolute
value; while brain with an intact BBB is expected to
display a low intercept and a “close to zero” slope).
Figure 1 Pre-post comparison method. The enhancement-distribution histograms of three representing regions (ROIs): eyeball, muscle and a
blood vessel. Black line represents an enhancement distribution in the muscle ROI (temporal muscle), green line for eyeball ROI (vitreous humor)
and red line demonstrates blood ROI (superior sagittal sinus). Author:
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The ability to use this parametric map for both
inter- and intra-subject comparison is an important
goal. However it is not straightforward: firstly due
to the inherent non-linearity of the MR signal
intensity with respect to contrast agent
concentration, which makes it impossible to
compare different scans quantitatively. Secondly,
variability in the administration of the contrast
agent and different physiological states of the
subject, affect the reproducibility of such scans.
Thus, data normalization should be considered to
overcome these issues. We propose two methods
which use the selection of a region of interest (ROI)
as a reference. The signal in the selected ROI is
then averaged and used in one of two ways:
(1) Parametric normalization: A linear curve is fitted
to the averaged signal of the selected ROI,
producing slope (SLROI) and intercept (INROI).
(2) Temporal normalization: The temporal signal in
each voxel is normalized to the corresponding
signal in the ROI. A linear curve is then fitted to
the normalized signal.
Choosing the reference ROI can be done either manu-
ally or automatically. Since the need for normalization is
also derived from the difference in contrast agent injec-
tion and dynamics, an option is to choose a blood vessel
as the ROI. Because of its size, the superior sagittal sinus
was chosen. Since the normalization is sensitive to the
ROI selection, another considerable approach is to use
the entire brain tissue as a reference ROI. An example of
the different normalization approaches are presented in
Figure 3. A patient with a glioblastoma multiforme was
scanned using the following MR protocol, performed on
a 1.5T Philips Intera scanner. The protocol included
anatomical scan (3D gradient echo, TR/TE/TI 8.6/3.5/
900 ms, FOV 240 mm, matrix 256 × 256, slice thickness
1.2 mm, 150 slices, flip angle 8°) and DCE-MRI se-
quence (standard spin echo, TR/TE=660/8 ms, FOV 240
mm, matrix 256 × 192, slice thickness 3 mm, 44 slices,
acquisition time: 3 minutes 14 seconds). The DCE-MRI
acquisition consisted of at least 7 longitudinal scans.
Gd-DTPA (10 ml) followed by a saline flush, was
injected approximately 3 minutes before the beginning
of the scan. Since the subject had a lesion on his left
hemisphere, the right hemisphere was used as ROI for
the relevant calculations. As can be seen in Figure 3, the
various linear fitting models provide comparable estima-
tions. It is noticeable, however, that among the suggested
methods, the temporal normalization to the blood vessel
(i.e. the superior sagittal sinus) provides the better con-
trast and a better linear fit as indicated by the improved
R2. Figure 4 shows the dynamic signal characteristics of
various tissues. The intensity in the blood vessel, in this
case the superior sagittal sinus, declined with time. Nor-
mal brain tissue remained approximately constant, while
lesion area is characterized by gradual signal increase,
representing contrast agent accumulation.
Results (preliminary)
The two proposed methods may provide an alterna-
tive to other BBB assessment approaches, in particu-
lar for cases where DCE-MRI scanning protocol is
not feasible or hard to apply. Nevertheless, these two
simplified methods still call for comprehensive valid-
ation studies. Figure 5 shows a preliminary qualitative
comparison between the Tofts two-compartment
method (5A), the linear model (5B) and the post-pre
method (5C). The three methods were applied to the
same subject with a lesion on his left hemisphere,
which was dynamically scanned using DCE-MRI im-
aging protocol. The dynamic scan was then digitally
under-sampled to accommodate the data to the post-
Figure 2 Semi-quantitative assessment for pre-post comparison method. (A) Enhancement distribution at range of 20%-100% defined with
muscle ROI. (B) Brain masking: CSF – blue, grey matter – red, white matter – green. (C) Permeable pixels at region defined by total brain region
mask. (D) Permeable pixels at region defined by brain tissue mask, excluding pixels relating to ventricles and subarachnoid space appearing in C.
(E) Clustering procedure applied to D. Single pixels and regions smaller than minimal size of 10 pixels were removed.
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pre and linear methods. All three methods detected
BBB dysfunction in and around the lesion. For the
modified Tofts method, enhanced permeability is
measured mostly in the core of the lesion, whereas in
the post-pre and the linear fitting models the
enhanced permeability appears at the margins of the
lesion at even greater magnitude than in the core.
This implies that while all three approaches may re-
port “dysfunctional” BBB, differences in relation to
the extent of a leaky barrier to a specific contrast
agent can be revealed. The proposed clinical alterna-
tive methods may, in some circumstances, even pro-
vide more information than the accepted quantitative
approach.
Figure 3 The linear dynamic method. A comparison of normalization methods and effect on the estimated parameters. The slope and
intercept are displayed on an arbitrary scale (different scale for each method), whereas the R2 is always scaled in the range of 0–1. The
parameters maps are smoothed using a median filter with a kernel of 3x3 voxels for display purpose.
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Discussion and conclusion
In this manuscript we described previous and new
attempts to assess BBB permeability quantitatively in
humans. While the DCE-MRI has been described for
more than a decade and shown to yield dysfunctional
BBB under different clinical conditions, it has not been
implemented in the routine clinical setup, nor tested for
its power in predicting patients’ outcome, or having any
contribution to clinical decision. A major limitation of
DCE-MRI is the complex imaging requirements, which
include initiation of the dynamic sequence prior to the
intravenous injection within the magnet, followed by
high frequency repeated scanning, that may force lower
spatial resolution or reduced coverage of brain regions.
The high temporal resolution is mainly needed for sam-
pling the rapid passage of tracer in the arterial phase,
which occurs within seconds following the injection.
Although highly informative, in particular for CBF as-
sessment, the first bolus pass of the contrast agent may
be neglected while retaining sufficient information in the
later stages after injection for BBB integrity assessment.
A dual-temporal resolution imaging protocol has been
proposed [12], based on an initial sequence with a high
acquisition rate to sample the first arterial pass followed
by a slower acquisition rate to sample the rest of the sig-
nal curve for a longer time. Although partially overcom-
ing the demanding high frequency requirement, it is still
based on the arterial input function and therefore tracer
injection must be done during scanning. This require-
ment possesses complexity, which cannot always be
overcome in the clinical setup, due to patient care or
treatment conditions or even on-site equipment and
hardware limitations. Another limitation is the low
spatial resolution and the limited brain volume required
when high acquisition rate is implemented. A further
issue is the computation resources needed for perme-
ability analysis of DCE-MRI, particularly if real-time
analysis is desired. A full brain DCE-MRI permeability
analysis can take up to an hour processing in a standard
work station. The proposed new methods presented in
this paper may provide a non-compromising alternative
to the full dynamic methods with a much less deman-
ding imaging protocol and computation time. In even
more restricting scenarios, when the patient is unable to
stay in the MR magnet for long enough periods, the
post-pre semi-quantitative method may serve as an op-
tion for BBB assessment. However, it is not as yet clear
whether these methods may reflect different levels of
Figure 4 Signal intensity changes in different tissues. Intensity is
relative to the intensity in the first scan.
Figure 5 A comparison of the permeability constant Ktrtans, ( min
-1) from Toft’s model (A), the normalized slope (sec-1) from the linear
model (B) and the difference percentage from the post-pre method (C). Quantitative comparison between the 3 methods is not trivial, so a
qualitative comparison is shown. False color scales reflect Ktrtans (A), normalized slope (B) and percent difference (C).
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BBB dysfunction. Another issue is the lack of compari-
son studies between the methodologies, their sensitivity,
or their ability to predict patient outcome.
Appendix
Quantitative analysis using DCE-MRI
In most cases, the pharmacokinetic models used for
quantification of permeability from contrast-enhanced
data are based on those developed for nuclear medicine.
These models are based on the two-compartment ex-
change model (2CXM) [13] in which the contrast agent
is accessible to two compartments within the overall tis-
sue volume (“voxel”) comprising blood (“intravascular”)
and tissue (“extravascular”) compartments. The latter is
usually divided into the extracellular- extravascular space
(EES) and the intracellular space. A common assump-
tion is that the contrast agent is impermeable to cell
boundaries so that these blood and tissue compartments
essentially represent plasma and EES spaces respectively.
The contrast agent is partitioned between these two
compartments with concentrations of Cp(t) and Ct(t), re-
spectively. The goal of contrast-enhanced techniques for
permeability quantification is to measure these two dy-
namic quantities and thereby derive permeability-related
measures according to the appropriate pharmacokinetic
model. Under normal circumstances, the contrast agent
is confined to the intravascular space and its passage
through the volume is controlled by blood flow. How-
ever, when BBB functions are impaired, leakage will
occur into the tissue (EES) compartment. This depends
not only on chemical characteristics of the contrast
agent, but also on the physiological characteristics of the
interface between the two compartments, i.e., the BBB.
Under conditions of BBB breakdown or impaired vascu-
larity, the contrast agent can escape the vasculature
and accumulate in the interstitial space of the tissue
(“extravasation”) and the concentration of tracer in the
tissue compartment is correspondingly increased.
As passage of the contrast agent through the blood
and into the tissue reflects the competing influences of
vascular perfusion and leakage, the 2CXM model
enables quantification of the capillary permeability-
surface area product, PS, and tissue plasma perfusion,
Fp. The “standard Tofts model” [14,15] is a simplification
of this two compartment model that assumes a negli-
gible contribution of the plasma space and therefore es-
sentially represents a one-compartment model. The
“modified Tofts model” reinstates the contribution of
the plasma compartment but makes a simplifying as-
sumption that the time taken for the contrast agent to
pass through this compartment (the plasma mean transit
time, MTT) is negligible [16].
Tracer-kinetic models form the quantitative basis of
all compartmental models and relate the tissue and
vascular concentrations of contrast agent according to
the following fundamental relationship:
Ct tð Þ ¼ FpCp tð Þ⊗R tð Þ ð1Þ
where R(t) is the impulse response function (IRF) of the
tissue and defines the fraction of contrast agent left in
the tissue at time, t. Cp(t) represents the “input” and is
ideally measured within an arterial vessel feeding the tis-
sue, thus representing the arterial input function (AIF).
Compartmental models such as 2CXM and Tofts var-
iants parameterize the IRF and perfusion terms in
Eq. (1) in terms of fundamental physiological quantities
related to the compartments and passage between them.
The simplest formulation, the standard Tofts model is
described by the following:
Ct tð Þ ¼ ktransCp tð Þ⊗ e
tktrans
ve ð2Þ
where ktrans, known as the transfer constant, defines the
rate of transfer from plasma to EES compartments in
(mL/g/min), and ve, known as the extracellular space
fraction, describes the fraction of the extravascular-
extracellular space occupied by tracer in (mL/g). ktrans
incorporates in its formulation both PS and Fp so that
these terms cannot be dissociated. By relating to Eq. (1),
it can be seen that the IRF is formulated as RTofts(t) =
(ktrans/Fp). exp(−tktrans/Ve) :
The modified Tofts model adds the contribution of
the plasma compartments:
Ct tð Þ ¼ ktransCp tð Þ⊗ e
tktrans
ve þ vpCp tð Þ ð3Þ
where vp is the fraction of the tissue volume occupied by
blood plasma [mL/g].
Derivation of hemodynamic parameters from the
concentration-time curves based on these models follow
the application of principles from tracer-kinetic analysis
[17]. Approaches follow either direct methods that de-
rive some of the parameters without explicitly determin-
ing the IRF, or deconvolution methods that derive the
full IRF via model-driven, model-free or parametric
approaches.
The MRI approach to contrast-enhanced permeability
quantification (principally DCE-MRI) calculates the
concentration-time curves, C(t), of a MR-visible contrast
agent from the dynamic MRI signal intensity, S(t),
according to MR principles. Gd-DTPA, a freely diffus-
ible, extracellular tracer, is the most common contrast
agent in these studies whose paramagnetic Gd3+ core
reduces the relaxation time, T1, in a concentration-
dependent manner. A set of T1-weighted images is
acquired, starting before a short bolus injection, and
continued as uptake by the tissue followed by washout
occurs. The presence of the contrast agent is indicated
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by an increase in signal intensity. The quantification ap-
proach relies on the assumption of a linear relationship
between the T1 relaxation rate (R1 = 1/T1) and the con-
trast agent concentration which is believed to be valid
for the relatively low concentrations expected in stan-
dard DCE-MRI studies. The most common MRI pulse
sequence used in these studies is a rapid 3D gradient
echo sequence for which the relationship between the
signal intensity and the R1 is well-defined but non-
linear. The concentration-time curves can be calculated
from the dynamically acquired images if a baseline
measurement of the relaxation time is performed before
bolus injection. For quantitative analysis, an accurate
measure of the AIF is also required. This can either be
derived from a population-averaged experimental meas-
urement [18] or directly measured in the subject within
an imaging region containing a cerebral artery or within
the drainage veins of the superior sagittal sinus.
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